NBDF/LinkedIn
Sep 10, 2025, 20:45
FDA Approves VONVENDI for Adults With All Types of von Willebrand Disease
National Bleeding Disorders Foundation (NBDF) shared on LinkedIn:
”Big news for the bleeding disorders community:
The FDA has expanded approval of VONVENDI® to include prophylactic use for adults with all types of von Willebrand disease (VWD).
This marks an important step forward in reducing bleeding episodes and improving quality of life.”
Read more here.
Stay updated on the emerging in the field of bleeding disorders with Hemostasis Today.
-
Feb 24, 2026, 16:18Salmaan Dalvi: Mapping Rare Diseases Across East and Central Africa
-
Feb 24, 2026, 16:16Wolfgang Miesbach: Game‑Changing Data on Intensive FVIII Replacement in Haemophilia A with Hypertrophic Synovium
-
Feb 24, 2026, 16:01Is It Safe to Briefly Stop Anticoagulation After VTE? – RPTH Journal
-
Feb 24, 2026, 15:58Anastasia Conti: Honored to Receive the Roche Foundation Grant for Independent Research in Onco-Hematology
-
Feb 24, 2026, 15:55Courtney Lawrence: Targeted Donor Screening Reduces Transfusion-Transmitted Babesia Cases
-
Feb 24, 2026, 15:30Aswin K Mohan: Practical Tips for Preparing Before, During, and After Blood Donation
-
Feb 24, 2026, 15:24Stéphanie Forté: The Hidden Burden of Stroke in Adults Living with Sickle Cell Disease
-
Feb 24, 2026, 15:13Tagreed Alkaltham: Equity in Emergency Care Through a Blood Bank Lens
-
Feb 24, 2026, 14:57Joseph Raffaele: Can Improving Mitochondrial Quality in Immune Cells Alter Immune Aging Markers?